Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial
Reduziertes Bestrahlungsvolumen versus konventionelles Bestrahlungsvolumen nach Induktionschemotherapie beim Nasopharynxkarzinom: offene, randomisierte Nichtunterlegenheits-Phase-3-Studie mit multizentrischem Design
CA: A Cancer Journal for Clinicians · 2025-06 · 75 (3) · 203-215
DOI: 10.3322/caac.21881 ↗Auf einen Blick
Bei LANPC war eine reduzierte Radiotherapie nach Induktionschemotherapie der konventionellen Volumenbestrahlung beim locoregionalen rezidivfreien Überleben nicht unterlegen. Toxizität war geringer, die Lebensqualität besser.
Fragestellung
Ist eine an das post-IC-Tumorvolumen angepasste Radiotherapie der konventionellen, am prä-IC-Tumorvolumen orientierten Radiotherapie beim LANPC nicht unterlegen?
Methode
Multizentrische, offene, randomisierte, kontrollierte Nichtunterlegenheitsstudie; Randomisierung 1:1 nach Induktionschemotherapie; primärer Endpunkt locoregionales rezidivfreies Überleben; Nichtunterlegenheitsmarge 8%.
Ergebnisse
445 Patient:innen wurden randomisiert (225 Post-IC, 220 Pre-IC). 3-Jahres-locoregionales rezidivfreies Überleben: 91,5 % vs. 91,2 %; Differenz 0,3 % (95 %-KI −4,9 bis 5,5). Grad 3-4-Toxizität war im Post-IC-Arm niedriger.
Schlussfolgerung der Autor:innen
In dieser Studie war die reduzierte Volumenradiotherapie der konventionellen Volumenradiotherapie beim locoregionalen rezidivfreien Überleben nicht unterlegen und war mit geringerer Toxizität sowie besserer Lebensqualität verbunden.
Kernaussagen
- 3-Jahres-locoregionales rezidivfreies Überleben: 91,5 % vs. 91,2 %
- Differenz 0,3 % (95 %-KI −4,9 bis 5,5)
- Weniger Grad 3-4-Toxizität und bessere QoL im Post-IC-Arm
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift CA: A Cancer Journal for Clinicians, online erschienen am 19.02.2025. Verfasst von Ling-Long Tang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and…. Hauptthemen laut MEDLINE: Induction Chemotherapy, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Radiation Injuries. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Guangzhou Municipal Health Commission.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Nearly 90% locoregionally advanced nasopharyngeal carcinoma (LANPC) responds to induction chemotherapy (IC) with significant tumor volume shrinkage. Radiotherapy always follows IC, and reduced volume has been proposed. However, the efficacy and safety of reduced‐volume radiotherapy is uncertain.
Methods
In this multi‐center, noninferiority, randomized, controlled trial, patients with LANPC who completed IC were randomly assigned (1:1) to receive reduced‐volume radiotherapy based on post‐IC tumor volume (Post‐IC group) or conventional volume radiotherapy based on pre‐IC tumor volume (Pre‐IC group). The primary endpoint was locoregional relapse‐free survival, with a noninferiority margin of 8%. Secondary endpoints comprised adverse events, and quality of life (QoL).
Results
Between August 7, 2020, and May 27, 2022, 445 patients were randomly assigned to Post‐IC ( n = 225) or Pre‐IC ( n = 220) groups. The average volume receiving radical dose was 66.6 cm 3 in Post‐IC group versus 80.9 cm 3 . After a median follow‐up of 40.4 months, the 3‐year locoregional relapse‐free survival was 91.5% in the Post‐IC group versus 91.2%, with a difference of 0.3% (95% confidence interval −4.9% to 5.5%). The incidence of grade 3‐4 radiation‐related toxicity was lower in the Post‐IC group including: acute mucositis (19.8% vs 34.1%), late otitis media (9.5% vs 20.9%) and late dry month (3.6% vs 9.5%). The Post‐IC group had better QoL for global health status, physical functioning, emotional functioning, dry mouth and sticky saliva.
Conclusions
In this trial, reduced‐volume radiotherapy was noninferior to conventional volume radiotherapy in locoregional relapse‐free survival, and was associated with lower toxicities and improved QoL. (ClinicalTrials.gov identifier NCT04384627).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Su…
- Nasopharyngeal Head and Neck Carcinoma Radiotherapy Department, Zhongshan City People's Hospital, Zhongshan, China.
- Department of Nasopharyngeal Oncology, First People's Hospital of Foshan, Foshan, China.
- Department of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.
- Clinical Trials Center, Sun Yat-sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Ling-Long Tang, Lin Chen, Cheng-Long Huang, Wen-Fei Li, Yu-Pei Chen, Yuan Zhang, Xu Liu, Cheng Xu, Yin Zhao, Na Liu, Fang-Yun Xie, Rui Guo, Ying Sun, Jun Ma
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- National Natural Science Foundation of China
- Guangzhou Municipal Health Commission
- Cancer Innovative Research Program of Sun Yat-sen University Cancer Center
- Sun Yat-sen University Clinical Research 5010 Program
- Audiology Development Foundation of China
- Overseas Expertise Introduction Project for Discipline Innovation
Zitieren
APA
Tang, L. L., Chen, L., Xu, G. Q., Zhang, N., Huang, C. L., Li, W. F., Mao, Y. P., Zhou, G. Q., Lei, F., Chen, L. S., Huang, S. H., Chen, L., Chen, Y. P., Zhang, Y., Liu, X., Xu, C., Zhao, Y., Li, J. B., Liu, N., …, & Ma, J. (2025). Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial. CA: A Cancer Journal for Clinicians, 75(3), 203-215. https://doi.org/10.3322/caac.21881
Vancouver
Tang LL, Chen L, Xu GQ, Zhang N, Huang CL, Li WF, et al. Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial. CA: A Cancer Journal for Clinicians. 2025;75(3):203-215. doi:10.3322/caac.21881
BibTeX
@article{Tang2025,
author = {Tang, Ling-Long and Chen, Lin and Xu, Gui-Qiong and Zhang, Ning and Huang, Cheng-Long and Li, Wen-Fei and Mao, Yan-Ping and Zhou, Guan-Qun and Lei, Feng and Chen, Lu-Si and Huang, Shao Hui and Chen, Lei and Chen, Yu-Pei and Zhang, Yuan and Liu, Xu and Xu, Cheng and Zhao, Yin and Li, Ji-Bin and Liu, Na and Xie, Fang-Yun and Guo, Rui and Sun, Ying and Ma, Jun},
title = {Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial},
journal = {CA: A Cancer Journal for Clinicians},
year = {2025},
volume = {75},
number = {3},
pages = {203--215},
doi = {10.3322/caac.21881}
}
EUVIMED